P. Jayarajan

发表

Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

A. Atri, R. Nirogi, J. Cummings, 2022, Alzheimer's & dementia.

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

R. Nirogi, J. Cummings, A. Shinde, 2022, Neurology and Therapy.

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity.

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2019, Journal of medicinal chemistry.

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

R. Nirogi, J. Cummings, A. Shinde, 2022, Neurology and Therapy.

Comparison of whole body and head out plethysmography using respiratory stimulant and depressant in conscious rats.

R. Nirogi, P. Jayarajan, Dhanalakshmi Shanmuganathan, 2012, Journal of pharmacological and toxicological methods.

Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2021, Psychopharmacology.

Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2015, European journal of medicinal chemistry.

Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.

R. Nirogi, M. Rasheed, Sugin Lal Jabaris, 2011, European journal of pharmacology.

α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain.

R. Nirogi, P. Jayarajan, R. Abraham, 2013, European journal of pharmacology.

Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligands.

R. Nirogi, P. Dubey, G. Bhyrapuneni, 2011, Bioorganic & medicinal chemistry letters.

Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task

R. Nirogi, V. Kandikere, G. Bhyrapuneni, 2012, Brain Research.

Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2022, Psychopharmacology.

1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

Abdul Rasheed Mohammed, R. Nirogi, A. Shinde, 2021, ChemMedChem.

Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders

R. Nirogi, G. Bhyrapuneni, Arunkumar Manoharan, 2021, Journal of psychopharmacology.

SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization

R. Nirogi, G. Bhyrapuneni, N. Muddana, 2019, Behavioural pharmacology.

Simultaneous monitoring of electroencephalographic characteristics in animals subjected to behavioral tests: a preclinical investigation

R. Nirogi, G. Bhyrapuneni, V. Benade, 2017, Behavioural pharmacology.

Copepods of the family Ergasilidae (Poecilostomatoida) parasitic on coastal fishes of Kerala, India

S. Radhakrishnan, J. Ho, P. Jayarajan, 1992 .

Indole-3-piperazinyl derivatives: novel chemical class of 5-HT(6) receptor antagonists.

R. Nirogi, V. Kandikere, P. Dubey, 2011, Bioorganic & medicinal chemistry letters.

Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.

R. Nirogi, M. Gampa, G. Bhyrapuneni, 2012, Journal of medicinal chemistry.

N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT₆ receptor antagonists.

R. Nirogi, V. Kandikere, P. Dubey, 2012, Bioorganic & medicinal chemistry letters.

Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders

Abdul Rasheed Mohammed, R. Nirogi, J. Cummings, 2023, Biomolecules.

Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease.

Abdul Rasheed Mohammed, R. Nirogi, G. Bhyrapuneni, 2017, Journal of medicinal chemistry.

5-HT_6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids

R. Nirogi, G. Bhyrapuneni, A. Shinde, 2015, Pharmacological reports : PR.

Comparison of manual and automated filaments for evaluation of neuropathic pain behavior in rats.

R. Nirogi, P. Jayarajan, Dhanalakshmi Shanmuganathan, 2012, Journal of pharmacological and toxicological methods.

Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists.

Abdul Rasheed Mohammed, R. Nirogi, N. Muddana, 2018, Journal of medicinal chemistry.

Aripiprazole in an Animal Model of Chronic Alcohol Consumption and Dopamine D2 Receptor Occupancy in Rats

R. Nirogi, V. Kandikere, G. Bhyrapuneni, 2013, The American journal of drug and alcohol abuse.

Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses

Abdul Rasheed Mohammed, R. Nirogi, J. Cummings, 2022, International journal of geriatric psychiatry.

Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling.

Abdul Rasheed Mohammed, R. Nirogi, R. Subramanian, 2023, European journal of pharmacology.

Chronic treatment with a selective 5-HT6 receptor antagonist alters the behavioral and neurochemical effects of ethanol in young adult rats

R. Nirogi, N. Muddana, A. Shinde, 2016, Behavioural pharmacology.

Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72s (DRL-72s) schedule in rats: involvement of the serotonergic receptors in restoring the deficits.

R. Nirogi, A. Shinde, P. Jayarajan, 2013, European journal of pharmacology.

Reinforcement Learning Concepts Ministering Smart City Applications Using IoT

R. Kanthavel, Fahad Algarni, R. Dhaya, 2020 .

SUVN-502, POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST: PROOF-OF-CONCEPT STUDY DESIGN IN MODERATE ALZHEIMER’S DISEASE PATIENTS

R. Nirogi, K. Mudigonda, A. Shinde, 2016, Alzheimer's & Dementia.

Comparison of whole body and head out plethysmography using respiratory stimulant and depressant in conscious rats.

R. Nirogi, P. Jayarajan, Dhanalakshmi Shanmuganathan, 2012, Journal of pharmacological and toxicological methods.

Hits and misses with animal models of narcolepsy and the implications for drug discovery

R. Nirogi, V. Goyal, V. Benade, 2024, Expert opinion on drug discovery.

Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.

R. Nirogi, M. Rasheed, Sugin Lal Jabaris, 2011, European journal of pharmacology.